Switch theme
Sign up to access all valuation multiples
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
2010
14.9K+
LTM Revenue $796M
LTM EBITDA $122M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alembic Pharmaceuticals has a last 12-month revenue (LTM) of $796M and a last 12-month EBITDA of $122M.
In the most recent fiscal year, Alembic Pharmaceuticals achieved revenue of $781M and an EBITDA of $125M.
Alembic Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alembic Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $796M | XXX | $781M | XXX | XXX | XXX |
| Gross Profit | $581M | XXX | $571M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $122M | XXX | $125M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $89.4M | XXX | $85.4M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $69.9M | XXX | $68.3M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $130M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alembic Pharmaceuticals's stock price is INR 1017 (or $12).
Alembic Pharmaceuticals has current market cap of INR 200B (or $2.3B), and EV of INR 212B (or $2.5B).
See Alembic Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.3B | XXX | XXX | XXX | XXX | $0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alembic Pharmaceuticals has market cap of $2.3B and EV of $2.5B.
Alembic Pharmaceuticals's trades at 3.2x EV/Revenue multiple, and 20.4x EV/EBITDA.
Equity research analysts estimate Alembic Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alembic Pharmaceuticals has a P/E ratio of 33.5x.
See valuation multiples for Alembic Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 20.3x | XXX | 20.4x | XXX | XXX | XXX |
| EV/EBIT | 27.7x | XXX | 29.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 33.5x | XXX | 33.8x | XXX | XXX | XXX |
| EV/FCF | -68.1x | XXX | -88.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlembic Pharmaceuticals's last 12 month revenue growth is 11%
Alembic Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
Alembic Pharmaceuticals's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alembic Pharmaceuticals's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alembic Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alembic Pharmaceuticals acquired XXX companies to date.
Last acquisition by Alembic Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Alembic Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alembic Pharmaceuticals founded? | Alembic Pharmaceuticals was founded in 2010. |
| Where is Alembic Pharmaceuticals headquartered? | Alembic Pharmaceuticals is headquartered in India. |
| How many employees does Alembic Pharmaceuticals have? | As of today, Alembic Pharmaceuticals has 14.9K+ employees. |
| Who is the CEO of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's CEO is Mr. Chirayu R. Amin. |
| Is Alembic Pharmaceuticals publicy listed? | Yes, Alembic Pharmaceuticals is a public company listed on BOM. |
| What is the stock symbol of Alembic Pharmaceuticals? | Alembic Pharmaceuticals trades under 533573 ticker. |
| When did Alembic Pharmaceuticals go public? | Alembic Pharmaceuticals went public in 2011. |
| Who are competitors of Alembic Pharmaceuticals? | Similar companies to Alembic Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's current market cap is $2.3B |
| What is the current revenue of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's last 12 months revenue is $796M. |
| What is the current revenue growth of Alembic Pharmaceuticals? | Alembic Pharmaceuticals revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Alembic Pharmaceuticals? | Current revenue multiple of Alembic Pharmaceuticals is 3.1x. |
| Is Alembic Pharmaceuticals profitable? | Yes, Alembic Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's last 12 months EBITDA is $122M. |
| What is Alembic Pharmaceuticals's EBITDA margin? | Alembic Pharmaceuticals's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Alembic Pharmaceuticals? | Current EBITDA multiple of Alembic Pharmaceuticals is 20.3x. |
| What is the current FCF of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's last 12 months FCF is -$36.4M. |
| What is Alembic Pharmaceuticals's FCF margin? | Alembic Pharmaceuticals's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of Alembic Pharmaceuticals? | Current FCF multiple of Alembic Pharmaceuticals is -68.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
